[Correspondence] Therapeutic drift or formulation drift: avoiding misconceptions about rifaximin and antimicrobial resistance in cirrhosis – Authors' reply
We thank Carmelo Scarpignato and Manuel Romero-Gómez for their thoughtful Correspondence, and we agree on most of the key points made. Rifaximin remains a valuable drug, its place in the secondary prevention of recurrent overt hepatic encephalopathy is secure, and antimicrobial r
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.